DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that
stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying,
and reduces appetite and food intake. Therapeutic approaches for enhancing ... Cited by 416 - Related articles - All 10 versions
- ►diabetesjournals.org DJ Drucker - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic
peptide (GIP) exert important effects on β-cells to stimulate glucose-dependent
insulin secretion. Both peptides also regulate β-cell proliferation and ... Cited by 284 - Related articles - All 13 versions
- ►diabetesjournals.org KB Degn, CB Juhl, J Sturis, G Jakobsen, B … - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for
treating type 2 diabetes. We explored the effect of short-term (1 week)
treatment with a GLP-1 derivative, liraglutide (NN2211), on 24-h dynamics ... Cited by 170 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org CF Deacon - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide (GLP)-1 is an incretin hormone with potent
glucose-dependent insulinotropic and glucagonostatic actions, trophic effects on
the pancreatic β-cells, and inhibitory effects on gastrointestinal ... Cited by 155 - Related articles - BL Direct - All 5 versions
M Bayes, X Rabasseda, JR Prous - Methods and findings in experimental and clinical …, 2006 - journals.prous.com Contributing Editors: P. Cole, C. Orellana, JA Vallès, RM a . Antonijoan, KP
Mohana Priya, M. Priya, V. Renuga, R. Sree Lekha, B. Priya, A. Tomillero, G.
Krithiga and E. Banu Rekha. Cited by 148 - Related articles - All 9 versions
- ►aspetjournals.org KE Mayo, LJ Miller, D Bataille, S Dalle, B … - Pharmacological reviews, 2003 - ASPET Peptide hormones within the secretin-glucagon family are expressed in endocrine
cells of the pancreas and gastrointestinal epithelium and in specialized neurons
in the brain, and subserve multiple biological functions, including ... Cited by 143 - Related articles - BL Direct - All 7 versions
- ►physiology.org B Rolin, MO Larsen, CF Gotfredsen, CF … - American Journal of Physiology- Endocrinology And …, 2002 - Am Physiological Soc NN2211 is a long-acting, metabolically stable glucagon-like peptide-1 (GLP-1)
derivative designed for once daily administration in humans. NN2211 dose
dependently reduced the glycemic levels in ob/ob mice, with ... Cited by 130 - Related articles - BL Direct - All 4 versions
- ►endojournals.org JJ Meier, B Gallwitz, S Salmen, O Goetze, JJ … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc The effects of different iv doses of glucagon-like peptide 1 (GLP-1) on glucose
homeostasis and gastric emptying were compared in patients with type 2 diabetes.
Twelve patients with type 2 diabetes received three different infusion ... Cited by 122 - Related articles - BL Direct - All 5 versions
- ►endojournals.org F Fehse, M Trautmann, JJ Holst, AE Halseth … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Context: First-phase insulin secretion (within 10 min after a sudden rise in
plasma glucose) is reduced in type 2 diabetes mellitus (DM2). The incretin
mimetic exenatide has glucoregulatory activities in DM2, including glucose- ... Cited by 123 - Related articles - BL Direct - All 4 versions
JJ Holst - Diabetes/Metabolism Reviews - interscience.wiley.com GLP-1 is a peptide hormone from the intestinal mucosa. It is secreted in
response to meal ingestion and normally functions in the so-called ileal brake,
that is, inhibition of upper gastrointestinal motility and secretion when ... Cited by 120 - Related articles - BL Direct - All 4 versions
